Björklund Pharma

Advancing healthcare and wellness

  • Home
  • Company
  • Pipeline
  • Publications
  • Media
  • Contact

Joint and Bone Health (under revision)

Product Candidate

JointEase

JointEase is a dietary supplement developed to provide nutritional support for joints and connective tissues. The product combines collagen peptides with selected botanical extracts that have been traditionally used and scientifically investigated for their relevance to joint comfort, mobility, and musculoskeletal well-being.

Each capsule of JointEase contains 500 mg collagen peptides, 50 mg Boswellia serrata extract (standardized to contain 65% boswellic acids), 40 mg Devil’s Claw extract (standardized to contain 5% harpagosides), 25 mg ginger root extract (standardized to contain 5% gingerols), 10 mg bromelain (from pineapple stem), and 15 mg willow bark extract (standardized to contain 15% salicin).

Collagen peptides are structural proteins naturally present in cartilage and other connective tissues. Supplementation with collagen peptides has been studied in people with joint complaints and is widely used in products intended to support joint integrity, flexibility, and everyday mobility.

Boswellia serrata extract provides boswellic acids, which have been examined in experimental and clinical studies for their ability to influence mediators of inflammation. Boswellia is commonly used in formulations aimed at supporting joint comfort and maintaining joint function, especially under mechanical load.

Devil’s Claw (Harpagophytum procumbens) has a long history of traditional use in musculoskeletal and joint applications. Extracts standardized for harpagosides have been investigated for their potential to support mobility and ease everyday joint discomfort.

Ginger root extract (Zingiber officinale), standardized for gingerols, has been studied for its anti-inflammatory and analgesic properties. Ginger is used in supplements intended to support musculoskeletal comfort and help maintain joint function in the context of an active lifestyle.

Bromelain is a proteolytic enzyme derived from pineapple stem. It has been investigated for its effects on tissue permeability and inflammatory mediators and is included in formulations intended to support recovery after physical strain and to help maintain normal tissue comfort.

Willow bark extract (Salix alba) is a natural source of salicin and has a long tradition of use for mild pain and musculoskeletal discomfort. Standardized extracts have been studied for their influence on prostaglandin pathways and their role in supporting the body’s physiological response to minor pain and strain.

JointEase is intended for adults who wish to support joint flexibility, everyday mobility, and musculoskeletal comfort as part of a balanced lifestyle. A typical recommended intake is one capsule daily, preferably with a meal, or as advised by a healthcare professional. The recommended daily dose should not be exceeded.

As with any supplement, individual responses can vary. The ingredients in InBio JointEase are generally well tolerated, but some people may experience mild digestive discomfort or hypersensitivity reactions. Because several components, including Boswellia, ginger, willow bark, and bromelain, may interact with certain medicines (for example, anticoagulants, antiplatelet agents, or anti-inflammatory drugs), individuals taking medication, those with chronic health conditions, pregnant or breastfeeding women, and those scheduled for surgery should consult a healthcare professional before using this product.

Combined use

Some individuals may consider using JointEase together with JointFlex or other joint-support formulations. Any combined use should respect the recommended daily doses of each product and be discussed with a healthcare professional, particularly when other medications or medical conditions are present.

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Company News

  • New COVID-19 Research Provides Insights on the Crucial Role of Zinc in Protein Targets of Drugs That Block SARS-CoV-2 Infection
  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2025 Björklund Pharma AS